Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.
Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G, Zhang Q, Liberati AM, Cao J, Yang H, Hao S, Hu J, Zhou K, Petrini M, Russo F, Zhang H, Sang W, Ji J, Ferreri AJM, Damaj GL, Liu H, Zhang W, Ke X, Ghiggi C, Huang S, Li X, Yao H, Paik J, Novotny W, Zhou W, Zhu H, Zinzani PL. Bachy E, et al. Among authors: ferreri ajm. Blood Adv. 2023 Aug 22;7(16):4435-4447. doi: 10.1182/bloodadvances.2022009575. Blood Adv. 2023. PMID: 37276067 Free PMC article. Clinical Trial.
Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Savage KJ, et al. Crit Rev Oncol Hematol. 2011 Sep;79(3):321-9. doi: 10.1016/j.critrevonc.2010.07.007. Epub 2010 Aug 10. Crit Rev Oncol Hematol. 2011. PMID: 20702104 Review.
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJM, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. Conconi A, et al. Among authors: ferreri ajm. Ann Oncol. 2011 Mar;22(3):689-695. doi: 10.1093/annonc/mdq416. Epub 2010 Sep 1. Ann Oncol. 2011. PMID: 20810546 Free article. Clinical Trial.
Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ, Govi S, Pileri SA, Savage KJ. Ferreri AJ, et al. Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302. doi: 10.1016/j.critrevonc.2012.02.005. Epub 2012 Mar 21. Crit Rev Oncol Hematol. 2012. PMID: 22440390 Review.
Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ, Govi S, Pileri SA, Savage KJ. Ferreri AJ, et al. Crit Rev Oncol Hematol. 2013 Feb;85(2):206-15. doi: 10.1016/j.critrevonc.2012.06.004. Epub 2012 Jul 11. Crit Rev Oncol Hematol. 2013. PMID: 22789917 Free article. Review.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C. Iannitto E, et al. Among authors: ferreri ajm. Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8. Br J Haematol. 2018. PMID: 30407629 Free article. Clinical Trial.
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Ferreri AJM, et al. Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270. Blood Adv. 2020. PMID: 32766857 Free PMC article. Clinical Trial.
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5. Lancet Haematol. 2021. PMID: 33513372 Free PMC article. Clinical Trial.
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, Skrypets T, Horwitz SM, De Souza CA, Radford JA, Bobillo S, Prates MV, Ferreri AJM, Chiattone C, Spina M, Vose JM, Chiappella A, Laszlo D, Marino D, Stelitano C, Federico M. Shustov A, et al. Among authors: ferreri ajm. Blood Adv. 2021 Feb 9;5(3):640-648. doi: 10.1182/bloodadvances.2020001581. Blood Adv. 2021. PMID: 33560375 Free PMC article.
335 results